Alcohol and tobacco use in cocaine-dependent participants provided treatment with buprenorphine/naloxone and naltrexone

March 2, 2016

Aims: Many individuals with cocaine use disorders also use alcohol and tobacco. A recent study conducted by NIDA’s Clinical Trials Network investigated pharmacotherapy for treatment of cocaine use disorders and also assessed alcohol and tobacco use. (Source: Drug and Alcohol Dependence) MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the […]

Read the full article →

Intranasal buprenorphine alone and in combination with naloxone: Reinforcing efficacy and abuse liability in physically dependent opioid abusers

March 2, 2016

Aims: Buprenorphine/naloxone (BUP/NX) was designed to prevent misuse by the intravenous (IV) route, as high naloxone IV bioavailability may precipitate withdrawal. We previously demonstrated that intranasal (IN) administration of BUP/NX results in appreciable absorption of naloxone. The present study explored whether IN BUP/NX has lower abuse potential and reinforcing efficacy compared to IN BUP alone […]

Read the full article →

Pilot study of atomoxetine for BUP/NX-maintained patients with co-occurring opioid and ATS use disorder

March 2, 2016

Aims: To evaluate the tolerability, acceptability, and potential efficacy of the selective norepinephrine transporter inhibitor atomoxetine for treating amphetamine-type stimulant (ATS) use disorder in patients receiving buprenorphine/naloxone (BUP/NX). (Source: Drug and Alcohol Dependence)

Read the full article →

The Cocaine Use Reduction with Buprenorphine study: Cocaine use findings

March 2, 2016

Aims: The Cocaine Use Reduction with Buprenorphine (CURB) study, conducted under the National Drug Abuse Treatment Clinical Trials Network, investigated the safety and effectiveness of buprenorphine/naloxone (BUP, as Suboxone®) provided on a platform of extended-release injectable naltrexone (XR-NTX, as Vivitrol®) for reducing cocaine use in participants who met DSM- IV criteria for cocaine dependence and […]

Read the full article →

Low dose naloxone provides an abuse deterrent effect to buprenorphine

March 2, 2016

Webster LR, Smith MD, Unal C, Finn A (Source: Journal of Pain Research)

Read the full article →

Now comes the hard part: Turning national attention into action

March 2, 2016

An AMA Viewpoints post by Patrice A. Harris, MD, chair-elect of the AMA Board of Trustees A father of five in Charleston, W. Va., last month told President Obama at a public event that if it weren’t for the quick response of police and paramedics earlier this year, his daughter would have died from a drug overdose. […]

Read the full article →

Buprenorphine and Naloxone Compared With Methadone Treatment in Pregnancy

March 2, 2016

(Obstet Gynecol. 2015;125(2):363–368) (Source: Obstetric Anesthesia Digest) MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.

Read the full article →

Long‐term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi‐site trial

March 2, 2016

ConclusionsThere are few differences in long‐term outcomes between buprenorphine and methadone treatment for opioid dependence, and treatment with each medication is associated with a strong reduction in opioid use. This article is protected by copyright. All rights reserved. (Source: Addiction)

Read the full article →

Malmö Treatment Referral and Intervention Study (MATRIS)–effective referral from syringe exchange to treatment for heroin dependence: a pilot randomized controlled trial

March 2, 2016

ConclusionsA randomized controlled trial in a syringe exchange programme showed no evidence that a strength‐based case management intervention improved attendance for treatment over referral alone. Attendance rates were high in both groups. This article is protected by copyright. All rights reserved. (Source: Addiction)

Read the full article →

Medical treatments for opioid Use disorder in Iran: a randomized, double‐blind placebo‐controlled comparison of buprenorphine/naloxone and naltrexone maintenance treatment

March 2, 2016

ConclusionsAmong patients with opioid use disorder in Iran, sublingual buprenorphine/naloxone was associated with greater number of opioid‐negative urine tests and treatment retention than oral naltrexone, but not significantly greater initial abstinence duration or proportions with sustained abstinence. This article is protected by copyright. All rights reserved. (Source: Addiction)

Read the full article →

← Previous Entries

Next Entries →